Loading
A phase 3 trial of Capivasertib, Fulvestrant, Palbociclib, Ribociclib and Abemaciclib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) is a phase 3 interventional study registered as NCT04862663 by AstraZeneca, with 893 participants enrolled, started 2021-05-10 and due to reach its primary completion in 2027-11-01. Interventions recorded: Capivasertib, Fulvestrant, Palbociclib, Ribociclib and Abemaciclib.
Shares PI3K, AKT and mTOR inhibitors, Capivasertib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Capivasertib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Ribociclib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Fulvestrant and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Abemaciclib, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.